AHEALTH future business potential by promising, the company actively expanding the earned rate higher brand pharmaceutical products, and more over the patent of drugs to expand generic drug positive support of the products, and the friendly drug control policy. OSK Research bullish on the company's future earnings growth potential, its own brand products to higher revenue and lead to higher earn pieces, it's cough syrup (accounting for the 2011 financial annual turnover of 5%) and cardiovascular drugs The product sells well, the benefit over the patent of drugs, as well as positive impact from friendly control policy change and positive support. The company also has its own brand of pharmaceutical products, the third party's Yibo Shi Pharmacy also sells brand-name pharmaceuticals. 30% of turnover from own brand products, and the remaining 70 percent is the third-party pharmaceutical products. Expected in 2011-2016, $ 67 billion worth of drugs over the patent period, further expansion of generic drug products in the market space. The company plans to expand its brand pharmaceutical products to enhance the earning increase (about 40-50%), compare third-party products is about 10%. It is currently R & D Avex, Avo, Kaps and other brand product line. Its Malacca plant is nearly fully operational, but also increase another production shift to increase production. The company is one more than the patents of drugs manufacturers and third-party drug distributors involved in operating areas, including Singapore, Malaysia, Vietnam and Indonesia. 2011 to a market survey, in 2005, patented drugs accounted for 70% of the global pharmaceutical overhead, but to the 2015 material will fall to the level of 53%, because more drug patent of overdue due. The same time, the amount of overhead of the generic drugs from 20% in 2005 to 2015, Young rose to the level of 39%. The company's turnover for the past eight years compound annual growth rate reached 9.9 percent compound annual growth rate of the company's future earnings growth is expected to reach 16.6%. (Sin Chew Jit Poh / Finance)
Apex Healthcare Bhd's (AHB) 1HFY12 results were largely in line with our expectation. Its revenue of RM204.8m made up about 50.5% of our full-year target. Management has declared an interim dividend of 6.0 sen. We are maintaining our FV of RM3.84, pegged at its 10-year average PER of 9.5x, which suggests a potential upside of 23% from the current share price.
Hi, kcfan, this counter is rather slow and steady. Shows average ROE of 13% with practically low debt to equity ratio. What do u think of the prospect?
The market for generic drugs will grow, but competition is stiff. The prospect of AHEALTH depends on how well it sells to hospitals and clinics. Maybe people in this industry can give us a clue...
Ahealth cheating the market ? no panic selling, volume getting lesser & lesser, people buying higher at price. sounds like lot of quality investors here
no safety buffer for me, come down a bit. gostan gostan, you forgot to pick your garlic at kilometer 340 !
Nicole, this website has changed. It used to be able to access dividends and past performance... But it doesn't seem to work now? Aiyah. Even thestaronline also now so difficult to navigate!
HI Abundance, you can see the dividend payout in the disclosures tab. No i just bought this share this year too but it didn't drop after the dividend payout and been steady, so taking it like a long term FD and investment. Hard to get this share as the selling price and buying price is always a vast difference. So good luck to you :)
Congrats to u, Nicole! Pharma really sleeping lah. I think the JV with Saudi Arsbis not on. It keeps dropping or zzzzzz Stemlife also zzzzzz By the way what smart phone able to open the tabs above to see dividend?? My iPhone can't. So very inconvenient. Can someone who knows how to blog open a unhappy blog and ask administrator to revert to old format? It was more user friendly for sure!!
HI Abundance, patience.. pharma is also a good company, already making on Pharma too but still holding on long term for that one. Stemlife slow but it's meant for long term investment at least it is steady :) You manage to get some lots on Ahealth?
Wow! Super excited just exceeded RM5.00 in less than then days up 10%. wonder what is the big news coming out soon. Wishing for some free bonus issue than and increase my units. HAHAHA!!
Nicole, Looks like dividends paid 2x a year. Wonder why amended announcement of payout dividend same for feb and march for may is ssme ie 11 sen? Maybe the run up is also for dividend announcement in August? Then you Fatt tat lor! I was watching this stock when u mentioned it ... Didn't buy. Saw very good movement. Looking forward to sona listing so want to save some bullets to play
HI Abundance, ya this counter not easy to buy in as people want to sell at very high price. By the way, STEMLIFE is on the move now ;) Hit 0.335 today if the trends continue will hit RM0.40 soon. More people are investing in pharmaceutical and health related counters :)
Yup, this counter hard to get the price you want when the gap is very large, i only notice when the market really down then sellers willing to let go at lower price but limited quantity too. Steady counter, been uptrend for the last two years.
Introducing MY's First IPO Fund for Sophisticated Investors!
MQ Chat
New Update. Discover investment communities that resonate with your ideas
MQ Trader
M & A Value Partners IPO Equity Fund has been launched - Targeted 13% Return p.a
Latest Videos
0:17
New IPO: Carlo Rino Group Berhad, a leading fashion retailer of women’s handbags, footwear, and accessories, aims to list on the ACE Market!
MQ Trader 83 views | 15 h ago
0:17
New IPO: A homegrown air fragrance company, Vanzo Holdings Berhad aims to list on the Ace Market!
MQ Trader 212 views | 1 d ago
0:17
New IPO: Winstar Capital Berhad, a specialist in the extrusion of aluminium profiles and fabrication of aluminium ladders aims to list on the ACE Market!
MQ Trader 378 views | 2 d ago
0:17
New IPO: Topvision Eye Specialist Berhad, specializing in medical eye care services aims to list on the ACE Market!
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
kcfan
1,881 posts
Posted by kcfan > 2012-08-08 23:44 | Report Abuse
AHEALTH future business potential by promising, the company actively expanding the earned rate higher brand pharmaceutical products, and more over the patent of drugs to expand generic drug positive support of the products, and the friendly drug control policy.
OSK Research bullish on the company's future earnings growth potential, its own brand products to higher revenue and lead to higher earn pieces, it's cough syrup (accounting for the 2011 financial annual turnover of 5%) and cardiovascular drugs The product sells well, the benefit over the patent of drugs, as well as positive impact from friendly control policy change and positive support.
The company also has its own brand of pharmaceutical products, the third party's Yibo Shi Pharmacy also sells brand-name pharmaceuticals. 30% of turnover from own brand products, and the remaining 70 percent is the third-party pharmaceutical products. Expected in 2011-2016, $ 67 billion worth of drugs over the patent period, further expansion of generic drug products in the market space.
The company plans to expand its brand pharmaceutical products to enhance the earning increase (about 40-50%), compare third-party products is about 10%. It is currently R & D Avex, Avo, Kaps and other brand product line. Its Malacca plant is nearly fully operational, but also increase another production shift to increase production.
The company is one more than the patents of drugs manufacturers and third-party drug distributors involved in operating areas, including Singapore, Malaysia, Vietnam and Indonesia.
2011 to a market survey, in 2005, patented drugs accounted for 70% of the global pharmaceutical overhead, but to the 2015 material will fall to the level of 53%, because more drug patent of overdue due. The same time, the amount of overhead of the generic drugs from 20% in 2005 to 2015, Young rose to the level of 39%.
The company's turnover for the past eight years compound annual growth rate reached 9.9 percent compound annual growth rate of the company's future earnings growth is expected to reach 16.6%. (Sin Chew Jit Poh / Finance)